key: cord-0333322-1aanykgx
authors: Thompson, P.; Morgan, C. E.; Ngimbi, P.; Mwandagalirwa, K.; Ravelomanana, N.; Tabala, M.; Fathy, M.; Kawende, B.; Muwonga, J.; Misingi, P.; Luhata, C.; Mbendi, C.; Jhaveri, R.; Cloherty, G.; Kaba, D.; Yotebieng, M.; Parr, J. B.
title: Arresting Vertical Transmission of Hepatitis B Virus (AVERT-HBV) in the Democratic Republic of the Congo
date: 2021-03-20
journal: nan
DOI: 10.1101/2021.03.19.21253929
sha: 22a86394fe594e6cb948dfb446bea51f14d93582
doc_id: 333322
cord_uid: 1aanykgx

Background: Hepatitis B virus (HBV) remains endemic throughout sub-Saharan Africa despite the widespread availability of effective vaccines. We evaluated the feasibility of adding HBV testing and treatment of pregnant women and birth-dose vaccination of HBV-exposed infants to the HIV prevention of MTCT (PMTCT) program infrastructure in the Democratic Republic of the Congo (DRC), where HBV treatment and birth-dose vaccination programs are not established. Methods: As part of the HIV PMTCT program at two maternity centers in Kinshasa, DRC, pregnant women were screened for HBV at routine prenatal care registration. Pregnant women with high viral load and/or HBeAg positivity were offered tenofovir disoproxil fumarate (TDF). HBV-exposed infants received a birth-dose of HBV vaccine within 24 hours of life. The primary endpoint was the feasibility and acceptability of the study. Results: Of 4,016 women screened, 109 (2.7%) were HBsAg-positive. Ten of 91 (11.1%) women evaluated had high-risk disease. Of 88 infants, 60 (68.2%) received a birth-dose vaccine; of these, 46 (76.7%) received a timely birth-dose. No cases of HBV MTCT were observed in our cohort. There were no serious adverse events associated with TDF nor with birth-dose vaccine. The study procedures were highly acceptable (>80%) among mothers. Conclusions: Adding HBV screening and treatment of pregnant women and infant birth-dose vaccination to existing HIV PMTCT platforms is feasible in countries like the DRC. Birth-dose vaccination against HBV integrated within the current Expanded Programme on Immunization (EPI) and HIV PMTCT program could accelerate progress toward HBV elimination in Africa.

CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 20, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 INTRODUCTION 75 Viral hepatitis is a leading infectious killer globally, with hepatitis B virus (HBV) alone 76 accounting for nearly one million deaths annually. 1 Despite the existence of an effective vaccine, 77 the prevalence of HBV in sub-Saharan Africa (SSA) remains unacceptably high. Mother-to-child 78 transmission (MTCT) is a silent driver of the HBV epidemic. In the absence of any intervention, 79 70% to 90% of mothers with high-risk HBV (defined as a viral load ≥ 200,000 IU/mL and/or 80 HBV "e" antigen [HBeAg] positivity) will transmit the virus to their infants, compared to 10% to 81 40% of mothers who are HBeAg-negative. 2 The World Health Organization (WHO) 82 recommends that all infants receive a birth-dose of HBV vaccine as soon as possible after birth, 83

preferably within 24 hours, followed by at least two additional vaccine doses. 3 The three-dose 84 series provides ≥ 95% protection against HBV infection, but breakthrough transmission can occur 85 despite vaccination in infants born to women with high-risk HBV. 4, 5 In its 2020 guidelines on 86 HBV prevention of MTCT (PMTCT), the WHO recommends that HBV-infected women with 87 high-risk HBV receive antiviral prophylaxis from the 28 th week of pregnancy until or beyond 88 delivery to prevent breakthrough MTCT. 3, 6, 7 Most HIV-HBV co-infected women receive 89 tenofovir as part of their antiretroviral regimen. However, the feasibility of providing antiviral 90 prophylaxis for HBV mono-infected pregnant women in low-resource settings in SSA has yet to 91 be tested. 92

The prevalence of HBV in the Democratic Republic of the Congo (DRC) is 3·3%, with high 94 (2·2%) prevalence among children under age five, which correlates to approximately 450,000 95 Congolese children living with chronic HBV, and at risk for liver disease and premature death. 8,9 96 While HBV vaccine has been part of the DRC's Expanded Program on Immunization (EPI) since 97 6 Between September 24, 2018 and February 22, 2019, all pregnant women registering for 121 pretenatal services at either of the two clinics were provided group counseling on HBV and 122 PMTCT thereof, and were invited to be screened for HBV. Those who verbally agreed were 123 screened using point-of-care ALERE DETERMINE HBsAg testing (Abbott Diagnostics, Abbott 124 Park, Illinois). Pregnant women who tested positive were referred for evaluation and inclusion in 125 this feasibility study. To be eligible for prospective follow-up, pregnant women who screened 126

HbsAg-positive needed to meet the following additional criteria: 1) gestational age ≤ 24 weeks 127 (allowing time for viral load and HbeAg testing and return of results prior to initiation of 128 tenofovir treatment between 28-32 weeks' gestation), 2) intention to continue care at one of two 129 maternity centers throughout the pregnancy and postpartum period, and 3) not sick enough to be 130 hospitalized. Written informed consent was obtained in the participant's preferred language 131 (French or Lingala). At the time of the study, underage pregnant women (<18 years) were 132 considered emancipated minors in the DRC and were allowed to consent directly without 133 parental consent. 134

At the time of consent, a structured questionnaire was administered to collect information on 135 demographic and clinical characteristics. All women were followed through 24 weeks 136 postpartum, when they completed an exit questionnaire that assessed the acceptability of study 137 procedures. 138

All participants underwent venous blood collection at baseline to determine risk status for HBV, 139

including HBeAg (Abbott ARCHITECT HBeAg assay, Abbott Park, Illinois) and HBV DNA 140 (Abbott RealTime HBV viral load assay, Abbott Park, Illinois), performed at the National Blood 141

Transfusion Center and National AIDS Control Program laboratories in Kinshasa, respectively. 142

Baseline kidney (blood urea nitrogen and creatinine) and liver (aspartate aminotransferase or 143 7 AST, and alanine aminotransferase or ALT) function was evaluated in all enrolled women. 144

Women with a viral load ≥ 200,000 IU/mL and/or HBeAg positivity were considered at 'high-145 risk' for HBV MTCT and were further assessed for eligibility for prophylactic treatment with 146 tenofovir disoproxil fumarate (TDF). 3, 15, 16 Women with high-risk HBV, without signs of reduced 147 kidney function (glomerular filtration rate (GFR) <50 mL/min) or abnormal liver function (as 148 determined by the study physician), were initiated on once daily 300mg dosing of TDF (Gilead 149 Sciences, South San Francisco, CA) treatment between 28-32 weeks' gestation and continued 150 through 12-weeks' postpartum. We assured that any women with HIV-HBV co-infection were 151 on a TDF-containing regimen, per national guidelines. Details of additional follow-up 152 procedures for women with high-risk HBV can be found in the Supplementary Material. To 153 assess TDF adherence, tenofovir diphosphate (TFVdp) levels were measured at the University of 154 North Carolina's Eshelman School of Pharmacy using DBS samples collected from high-risk 155 women at delivery. TFVdp levels represent an average of expected adherence over a several 156 month period, as the medication has a long half-life in red blood cells. TFVdp concentrations in 157 DBS of 490, 980 and 1750 fmol/punch indicated a participant taking 2, 4 and 7 doses per week, 158 respectively, based on an expected 1.4-fold bias in concentrations from published thresholds. 17 159 All exposed infants were given a birth-dose of monovalent HBV vaccine (Euvax-B, 0·5 mL), as 160 soon as possible and ideally within 24 hours of life. The timing of birth and of vaccination were 161 recorded. Infants were monitored for at least 24 hours after receipt of vaccine, and adverse 162 reactions were recorded. Infants underwent point-of-care HBsAg testing at 24 weeks. 163

Feasibility was the key part of the program that was evaluated: the feasibility of screening 165 pregnant women to identify those at high risk for HBV MTCT and to provide them with antiviral 166 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 20, 2021. ;  8 prophylaxis, and the feasibility of administering the birth-dose vaccine to infants of women with 167

To assess the feasibility of viral prophylaxis for women at high risk of HBV MTCT, we 169 calculated the following proportions: 1) women who tested positive by HbsAg screening, 2) 170 HBsAg+ women who consented for enrollment, 3) eligible women with high-risk HBV who 171 accepted TDF prophylaxis, and 4) women on TDF who adhered to treatment as measured by a) 172 pill count, b) viral suppression at delivery (defined as HBV viral load < 200,000 IU/mL), and c) 173

TFVdp level. Acceptability of the program was assessed by calculating frequencies of aggregate 174 responses on the exit questionnaire. A predetermined cutoff of 80% reporting the program to be 175 "very acceptable" or "somewhat acceptable" on survey responses was deemed "acceptable". 176

Secondarily, we evaluated the safety of TDF prophylaxis by screening for adverse events, and 177 the percentage of women who developed ALT elevation during/after antiviral treatment. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) continuum are displayed in Figure 1 . One woman was withdrawn from the treatment program 197 due to a false pregnancy (study staff confirmed a negative urine pregnancy test despite report of 198 pregnancy by the woman); data from 90 women were therefore included. The median age of 199 enrolled women was 31 (IQR: 25,34) years and the median gestational age was 19 weeks (IQR: 200 15,22) ( Table 1) . Only one woman was co-infected with HIV and HBV; she received a TDF-201 based antiretroviral regimen. Reasons women elected not to enroll are shown in Figure 2 . Of the 202 90 women, ten (11·1%) had high-risk HBV; nine of ten were HBeAg positive and five of ten had 203 a high viral load. Women with high-risk HBV were younger and presented later in pregnancy 204 than women without high-risk HBV ( Table 1) . 205

Three women voluntarily withdrew and 12 were lost-to-follow-up by the time of the delivery 207 visit. Eleven women voluntarily withdrew by 24-weeks' postpartum, three women did not have 208 living children (two miscarriages and one stillbirth), one infant died, and 21 women were lost-to-209 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 20, 2021. ; https://doi.org/10.1101/2021.03.19.21253929 doi: medRxiv preprint 10 follow-up despite repeated efforts by the study team to contact them by telephone or in person 210 ( Figure 2) . Thus, 54 women (60·0%) completed the study through the 24-week postpartum visit. 211

Of the ten women with high-risk HBV, six (60·0%) were followed to study completion. Two 212 women with high-risk HBV voluntarily withdrew from the study; the first prior to initiation of 213 TDF, and the second after delivery. A third woman moved to another province in the DRC after 214 delivery, and a fourth was lost to follow-up (LTFU) after the 10-week visit. 215

A total of 88 infants were born to enrolled women. Overall, sixty of 88 infants (68·2%) received 217 a birth-dose of monovalent HBV vaccine; of these, 46 (76·7%) received a timely birth-dose 218 within 24 hours. Among 63 infants born at the two study facilities, 48 (76·2%) received a birth-219 dose, and 41 of 48 (85·4%) were timely. Among 25 infants born at an outside facility, 12 220 (48·0%) received a birth-dose, and five of 12 (41·7%) were timely. None of the infants were born 221 outside of a health facility. Figure 1B depicts the care continuum for infants, including reasons 222 for missed or untimely vaccination. No adverse events were reported related to the birth-dose. Of 223 53 infants tested at 24 weeks, zero (0%) tested positive for HBsAg, consistent with no HBV 224

Nine of ten (90·0%) women with high-risk HBV were initiated on TDF. One woman refused 227 therapy and withdrew from the study. Five of nine (55·6%) women achieved viral suppression 228 (<200,000 IU/mL) on TDF therapy by the time of delivery ( Figure 1A) ; the remaining four 229 women had decreased viral loads from enrollment to delivery, but not below 200,000 IU/mL 230 (Figure 3) . While all women taking TDF returned empty pill bottles and reported full adherence 231 per the exit survey, TFVdp levels suggested low adherence. Three of nine women delivered 232 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 20, 2021.

within 28 days of initiation of TDF therapy, so TFVdp cannot be interpreted. Of the remaining 233 six, three women had levels below the limit of quantification (BLQ), and one each with levels 234 reflecting <2 doses per week, 2-4 doses per week, and 4-7 doses per week (Figure 3) . All three 235 women with detectable TFVdp who initiated TDF therapy >28 days prior to delivery were virally 236 suppressed at delivery (Figure 3) . 237

There were no serious adverse events associated with TDF. One woman reported dizziness while 239 taking the medication; otherwise, no side effects were reported. Three women (33·3%) 240 developed rebound elevations of ALT (Supplementary Figure 1) , and two women (22·2%) 241 developed corresponding elevations of HBV DNA after stopping TDF at 12-weeks' postpartum. 242

These women were referred to the study gastroenterologist for further management, but none 243 attended their appointments. 244

All seven high-risk women followed through six months reported the act of taking TDF as "very 246 acceptable". Forty-eight of 54 women (88·9%) followed through 24-weeks' postpartum reported 247 having their blood drawn as "very acceptable," with only two women reporting this as "very" or 248 "somewhat unacceptable" (Figure 4) . Only four women reported the infant blood draw as 249 "somewhat" or "very unacceptable". Only one woman (1·9%) reported vaccination of her infant 250 as "very unacceptable". 251 252 DISCUSSION 253 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 20, 2021. ; https://doi.org/10. 1101 /2021 We demonstrate the feasibility of implementing a PMTCT of HBV program in the DRC using 254 existing HIV PMTCT and EPI infrastructure with a two-pronged approach: 1) screening and 255 treatment of HBV-positive pregnant women at high-risk for MTCT, and 2) provision of a birth-256 dose vaccine to HBV-exposed infants. Of the 53 HBV-exposed infants followed through 24 257 weeks, none were positive for HBV, indicating no vertical transmission. Even with vaccination, 258 the estimated risk of MTCT among infants born to women with high-risk HBV ranges from 20% 259 in Asia to 32% in Africa, compared to less than 1% for vaccinated infants born to Asian and 260

African women without high-risk features. 19 CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) Birth-dose vaccination was feasible in two high-volume maternity centers in urban Kinshasa, 276 DRC, and was largely acceptable to mothers. While we did not achieve vaccination within 24 277 hours of birth for all infants, this feasibility study demonstrates that a higher standard-of-care is 278 within reach in the DRC. We identified several barriers to timely administration of the birth-dose 279 that must be overcome as the country moves to universal birth-dose vaccination. First, many 280 women delivered at outside facilities rather than at one of the two study facilities. Potential CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 20, 2021. We uncovered a discordance between verbally reported adherence to TDF therapy and adherence 299 as measured by TFVdp levels. Only three of nine women had TFVdp levels suggesting that they 300 took at least two doses per week; two of these three women had viral load suppression at 301 delivery. This is in contrast to the nearly 100% adherence reported on exit surveys and via pill 302 counts (only empty bottles were returned). Changes in viral load and creatinine among women 303 taking TDF can be used as proxy measures of adherence but do not fully explain the discordance. 304

Further studies are needed to understand the drivers of poor adherence. 305

The strength of this study lies in its pragmatic, comprehensive approach. In line with recent 307 WHO guidelines for preventing HBV MTCT, we integrated HbsAg screening into an existing 308 HIV PMTCT program, leveraged laboratory infrastructure to identify and treat pregnant women 309 with high-risk HBV, and leveraged the existing EPI cold chain infrastructure to deliver birth-310 dose vaccination to exposed infants. This package of interventions is delivered routinely to 311 prevent HBV MTCT in the Global North, but not in Africa. We longitudinally followed HBV-312 infected women and their exposed infants through 24 weeks' postpartum to document adherence 313 to the cascade of care, side effects of birth-dose vaccine and TDF, and incidence of MTCT. 314 While most studies of HBV MTCT in Africa published to-date focus on HBV-HIV co-infection, 315 our cohort of mainly HBV mono-infected pregnant women is generalizable to settings in Africa 316

where HIV prevalence is low. 317 318 This study also had limitations. First, the sample size was relatively small. Yet, to the best of our 319 knowledge, this is the largest study of PMTCT of HBV among mono-infected pregnant women 320 in SSA performed to-date. Second, the absence of a control group prevented us from quantifying 321 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 20, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 15 the effectiveness of specific interventions. We were ethically obligated to provide effective HBV 322 prevention measures; other studies in African settings have described the natural history of 323 chronic HBV. 29 Third, we observed a high rate of LTFU in this study. While LTFU negatively 324 impacts our ability to determine incidence of MTCT, it is an expected feature of pragmatic 325 feasibility studies and consistent with postnatal follow-up patterns in the DRC. 18 Fourth, supply 326 chain disruption prevented us from completing planned laboratory comparisons of HBeAg and 327 viral load testing on DBS versus venous blood in-country. The COVID-19 pandemic bears some 328 responsibility for these challenges, but nascent HBV laboratory reagent supply chains are also to 329 blame. Delays in the return of laboratory results to some participants may have contributed to 330 withdrawal or LTFU. Unanticipated stockouts led to a lack of HBeAg results for three women at 331 enrollment; all three women were classified as low-risk for HBV MTCT based on their low viral 332 loads. Finally, the measurement of TFVdp levels from DBS may not accurately depict adherence 333 to TDF therapy. TFVdp is not sensitive for behavior change, as it represents an average of 334 adherence over several months. Furthermore, we cannot exclude the possibility of TFVdp 335 degradation during DBS preparation or transportation from the DRC, where ambient 336 temperatures and humidity are high. There is no clear threshold for how much tenofovir is 337 required to prevent HBV MTCT, but decreases in maternal HBV DNA prior to delivery are 338 associated with decreased risk of HBV MTCT. 6,7 Despite variable TFVdp levels, most women 339 did have a several log decline in HBV DNA. Even with these limitations, we successfully 340 implemented effective HBV PMTCT measures. 341

In conclusion, this study provides strong evidence in support of the WHO recommendation that 343 mother-to-infant HBV transmission can be prevented by building upon HIV PMTCT and EPI 344 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 20, 2021. ;  platforms in resource-constrained settings such as the DRC. Lessons learned from HIV PMTCT, 345 including how to improve retention and adherence to prophylaxis, can be leveraged to address 346 similar challenges in the HBV PMTCT program. Deploying a package of proven interventions 347 used routinely in the Global North but not widely adopted in Africa, we demonstrate the 348 feasibility of HBV MTCT prevention measures during routine care at two high-volume maternity 349 hospitals in Kinshasa. A two-pronged maternal screening/treatment and infant birth-dose 350 approach was acceptable to mothers, and no cases of HBV MTCT were observed. Though 351 obstacles must be overcome before roll-out of antiviral prophylaxis for pregnant women at high-352 risk of HBV MTCT, universal birth-dose HBV vaccination is a proven measure that should be 353 implemented in the DRC and throughout SSA. To meet WHO elimination goals by 2030, 30 354 countries with endemic HBV such as the DRC should adopt and implement WHO guidelines that 355 establish pathways for HBV PMTCT, 3 and should prioritize cross-cutting HBV prevention 356 measures that include birth-dose vaccination. 357 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 20, 2021. ;

We would like to thank all of the women who participated in this study. We also acknowledge 380 the staff at the maternity clinics, as well as provincial and national health authorities. We are 381 grateful for the support we have received from administrative staff at the University of North 382

Carolina and at Kinshasa School of Public Health. We also thank David Wohl for helpful advice 383 and and the UNC Clinical Pharmacology and Analytical Chemistry Core for supporting the 384 TFVdp assays. We grieve the loss of Professor Steven Meshnick, who played a major role in this 385 study and whose vision and mentorship were critical to its success. 386 387 Data Sharing Statement. Datasets will not be made publicly available because they contain 388 protected health information. However, the authors will share de-identified participant data, 389 alongside the study protocol, statistical analysis plan and analytic code, upon reasonable request 390 and with approval by an independent review committee ("learned intermediary"). 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 20, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 20, 2021. ; . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) Wealth quartiles were calculated from a principal component analysis including the following variables: people per household room, number of beds in household, number of radios in household, number of televisions in household, number of phones in household, number of refrigerators in household, ownership of a car, presence/absence of electricity in household, cooking with electricity, cooking with wood, and private water source.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 20, 2021. ; Figure 3 . Viral loads of women with high-risk disease across study timepoints by tenofovir diphosphate (TFVdp) level. TFVdp levels reflect average adherence over several months. *Imputed viral load from dried blood spot assay (see Supplementary Materials). ** Tenofovir disoproxil fumarate initiated within 28 days of delivery, before TFVdp steady-state is expected.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 20, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 20, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 

EASL clinical practice guidelines: Management of chronic hepatitis B virus infection

HIV viral suppression among pregnant 19

Systematic review with meta-analysis: the risk of